At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PLSE Pulse Biosciences
Market Closed 01-16 16:00:00 EST
14.25
+0.15
+1.06%
盘后14.25
+0.000.00%
17:16 EST
High14.56Low13.94Vol135.92K
Open14.07D1 Closing14.10Amplitude4.40%
Mkt Cap965.69MTradable Cap248.50MTotal Shares67.77M
T/O1.94MT/O Rate0.78%Tradable Shares17.44M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE)
Simply Wall St.  ·  01-13
New Cardiac Ablation Data and Board Appointment Might Change The Case For Investing In Pulse Biosciences (PLSE)
Assessing Pulse Biosciences (PLSE) Valuation After Upcoming nPulse Cardiac Study Data Presentation
Simply Wall St.  ·  01-09
Assessing Pulse Biosciences (PLSE) Valuation After Upcoming nPulse Cardiac Study Data Presentation
Pulse Biosciences Appoints Maria Sainz to Board of Directors
Reuters  ·  01-09
Pulse Biosciences Appoints Maria Sainz to Board of Directors
Pulse Biosciences Unveils Late-Breaking Data from nPulse Cardiac Catheter Study at AF Symposium
Reuters  ·  01-06
Pulse Biosciences Unveils Late-Breaking Data from nPulse Cardiac Catheter Study at AF Symposium
Pulse Biosciences to Present at J.P. Morgan Healthcare Conference
Reuters  ·  2025-12-30
Pulse Biosciences to Present at J.P. Morgan Healthcare Conference
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial
Simply Wall St.  ·  2025-12-23
Why Pulse Biosciences (PLSE) Is Up 8.0% After FDA Clears Pivotal Atrial Fibrillation Trial
BRIEF-Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  2025-12-20
BRIEF-Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pulse Biosciences Grants Inducement Stock Options to New Employees
Reuters  ·  2025-12-20
Pulse Biosciences Grants Inducement Stock Options to New Employees
Pulse Biosciences Wins FDA IDE Approval for nPulse Cardiac Catheter Study
Reuters  ·  2025-12-18
Pulse Biosciences Wins FDA IDE Approval for nPulse Cardiac Catheter Study
Pulse Biosciences Announces FDA Ide Approval to Initiate Its Npulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
THOMSON REUTERS  ·  2025-12-18
Pulse Biosciences Announces FDA Ide Approval to Initiate Its Npulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
Pulse Biosciences Partners with MD Anderson to Study Thyroid Cancer Treatment
Reuters  ·  2025-12-09
Pulse Biosciences Partners with MD Anderson to Study Thyroid Cancer Treatment
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors With Npulse™ Technology
THOMSON REUTERS  ·  2025-12-09
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors With Npulse™ Technology
BRIEF-Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  2025-11-22
BRIEF-Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pulse Biosciences Grants Stock Options to New Employees Under Inducement Plan
Reuters  ·  2025-11-22
Pulse Biosciences Grants Stock Options to New Employees Under Inducement Plan
Pulse Biosciences Updates Investors on Product Advancements
TIPRANKS  ·  2025-11-13
Pulse Biosciences Updates Investors on Product Advancements
Pulse Biosciences Inc. to Present at Stifel 2025 Healthcare Conference
Reuters  ·  2025-11-07
Pulse Biosciences Inc. to Present at Stifel 2025 Healthcare Conference
Pulse Biosciences FY2025 Q3 Earnings Call Summary and Q&A Highlights: Initial Revenue and Strategic Clinical Advancements
Earnings Call  ·  2025-11-06
Pulse Biosciences FY2025 Q3 Earnings Call Summary and Q&A Highlights: Initial Revenue and Strategic Clinical Advancements
Pulse Biosciences (PLSE) Earnings Transcript
Motley Fool Transcribing  ·  2025-11-06
Pulse Biosciences (PLSE) Earnings Transcript
Oppenheimer Keeps Their Buy Rating on Pulse Biosciences (PLSE)
TIPRANKS  ·  2025-11-06
Oppenheimer Keeps Their Buy Rating on Pulse Biosciences (PLSE)
Pulse Biosciences Q3 EPS $(0.29) Beats $(0.31) Estimate, Sales $86.000K Miss $500.000K Estimate
Benzinga  ·  2025-11-06
Pulse Biosciences Q3 EPS $(0.29) Beats $(0.31) Estimate, Sales $86.000K Miss $500.000K Estimate

Introduction

Company Name.
Pulse Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.
Issue price:
--